Kevin Killeen of Matrivax R&D Inc. in the U.S. proposes applying a novel technology which entraps many polysaccharide antigens in a protein matrix. If successful, this prototype platform could increase the breadth of serotypes currently covered by pneumococcal vaccines as well as reduce costs of vaccine production.
Grant ID
OPP1008306
Show on Hub
On
Show on Spoke
On
Follow-on Funding
Off
Lead Funding Organization
Initiatives
Principal Investigator
Award Manager
Individual Funder Information
Funding Organization
Funding Amount (in original currency)
100000.00
Funding Currency
USD
Funding Amount (in USD)
100000.00
Project Type
Project Primary Sector
Funding Date Range
-
Funding Total (In US dollars)
100000.00
Co-Funded
False